Postepy Dermatologii I Alergologii最新文献

{"title":"Chronic dermatoses affect not only sick individuals: a review of family and caregiver burden assessment tools.","authors":"Ewa Wójcik, Piotr K Krajewski, Jacek C Szepietowski","doi":"10.5114/ada.2024.141685","DOIUrl":"10.5114/ada.2024.141685","url":null,"abstract":"<p><strong>Introduction: </strong>The focus in dermatology has shifted from solely treating skin conditions to considering the quality of life (QoL) of patients and their family members.</p><p><strong>Aim: </strong>To identify and categorise instruments that assess the impact of chronic skin diseases on the QoL of family members and caregivers.</p><p><strong>Methods: </strong>A narrative review was conducted using the Scopus and Medline databases, with search terms related to QoL, dermatology, and family/caregivers. Articles published up to January 2024 were reviewed, and relevant instruments were categorised.</p><p><strong>Results: </strong>The search yielded 2799 papers, of which 153 were reviewed in detail. Twenty instruments were identified and categorised into generic, dermatology-specific, and disease-specific tools.</p><p><strong>Conclusions: </strong>The review highlights the importance of assessing family QoL in dermatology. Integrating these tools into clinical practice can enhance support for family members, improving overall patient care. Further development and refinement of these tools are necessary to capture the full impact on family QoL.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"433-445"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the correlation between the levels of HIF-1α and miR-199a in lesions and the psoriasis severity index.","authors":"Gang Miao, Jing Pan, Lingyan Wang, Fenfen Li","doi":"10.5114/ada.2024.143495","DOIUrl":"10.5114/ada.2024.143495","url":null,"abstract":"<p><strong>Introduction: </strong>The pathogenesis of psoriasis is complex. Previous bioinformatics studies have found differential expression of HIF-1α and miR-199 in psoriasis, but the correlation between miR-199a and HIF-1α and the severity of psoriasis is still unclear. This study found differential expression of HIF-1α and miR-199a levels in the skin lesions of patients with different degrees of psoriasis. HIF-1α mRNA and miR-199a are PASI influencing factors, and the levels of HIF-1 α and miR-199a in the skin lesions can serve as potential indicators for evaluating the severity index of psoriasis.</p><p><strong>Aim: </strong>To examine the relationships between the levels of HIF-1α and miR-199a and psoriasis severity.</p><p><strong>Material and methods: </strong>Sixty-five patients with psoriasis vulgaris treated from January 2023 to May 2024 were divided into a mild group (<i>n</i> = 16), a moderate group (<i>n</i> = 23), and a severe group (<i>n</i> = 26) according to the lesion area and severity index (PASI) score, and 40 healthy people were included in the control group (group A). The expression of HIF-1a and miR-199a in psoriatic lesions and normal skin tissues was detected by fluorescence quantitative PCR.</p><p><strong>Results: </strong>The level of miR-199a in lesions in the observation group (group B) was lower than that in group A, but the level of HIF-1αmRNA in group B was greater than that in group A. The level of miR-199a in moderate and severe psoriasis patients was lower than that in mild psoriasis patients, and that in severe psoriasis patients was lower than that in moderate psoriasis patients. HIF-1α mRNA in lesions was positively associated with the PASI in psoriasis patients, and the miR-199a level in lesions was positively associated with the PASI in psoriasis patients. Furthermore, taking the PASI as the dependent variable and HIF-1αmRNA and miR-199a with a linear relationship with the dependent variable as the independent variables, multiple stepwise regression analysis showed that HIF-1α mRNA and miR-199a influenced the PASI.</p><p><strong>Conclusions: </strong>HIF-1α and miR-199a are differentially expressed in the lesions of patients with different severities of psoriasis. The HIF-1α and miR-199a levels in lesions can be used as potential indices to evaluate the severity of psoriasis.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"521-524"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of acquired reactive perforating collagenosis after COVID-19 infection.","authors":"Shaoheng Wang, Xuefen Min, Xi Wang, Lifang Cheng, Liguo Qiu","doi":"10.5114/ada.2024.142575","DOIUrl":"10.5114/ada.2024.142575","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"536-537"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 15% 5-aminolevulinic acid and 10% 5-aminolevulinic acid photodynamic therapy for the treatment of acne vulgaris: a split-face randomized pilot study.","authors":"Natalia Brzezińska, Barbara Bulińska, Natalia Zawadzka, Gustaw Roter, Aneta Szczerkowska-Dobosz","doi":"10.5114/ada.2024.144417","DOIUrl":"10.5114/ada.2024.144417","url":null,"abstract":"<p><strong>Introduction: </strong>Acne vulgaris is a highly prevalent skin disorder, driving the ongoing search for innovative treatment modalities. While numerous studies have demonstrated the effectiveness of photodynamic therapy (PDT) in managing acne vulgaris, there remains a lack of clear guidlines regarding optimal treatment parameters.</p><p><strong>Aim: </strong>To assess the efficacy and safety of 10% concentration 5-aminolevulinic acid-(ALA) in comparison to 15% ALA PDT for treating facial acne vulgaris.</p><p><strong>Material and methods: </strong>A randomized, double-blind, split-face clinical trial was conducted on 25 patients with moderate to severe acne (<i>Leeds grades 2-4</i>). Patients were randomly assigned to two groups with different ALA concentrations applied on one cheek, while a placebo was applied on the other side. After a 1.5-hour incubation, illumination with 633 nm red light from a Light Emitting Diode (LED) lamp (96 J/cm²) was performed in three sessions with 7-10 days' intervals. Treatment effectiveness was assessed by the lesion reduction rate based on lesion counts before the study, after each session, and at 4 and 8 weeks after the last session.</p><p><strong>Results: </strong>Both 15% and 10% ALA-PDT treatments demonstrated significant reductions in inflammatory acne lesion counts compared to the placebo: 10% ALA-PDT showed a reduction of 27.36% versus 12.64% for the placebo (<i>p</i> = 0.04), while 15% ALA-PDT showed a reduction of 40.45% compared to 13.41% (<i>p</i> < 0.01). However, there was no significant difference between ALA-PDT and placebo in treating non-inflammatory lesions. Additionally, there was no difference between the effectiveness of 10% and 15% ALA in reducing any type of acne lesions.</p><p><strong>Conclusions: </strong>ALA-PDT is effective in treating acne vulgaris. However, ALA-PDT provides an advantage over red light only for inflammatory acne lesions. The study indicates that higher concentrations of ALA do not result in more significant reductions in acne lesions.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"479-486"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a correlation between serum and faecal calprotectin levels and the disease severity in patients with moderate-to-severe plaque psoriasis? A pilot study.","authors":"Karina Polak, Tomasz Muszyński, Aleksandra Frątczak, Bartosz Miziołek, Beata Bergler-Czop","doi":"10.5114/ada.2024.142576","DOIUrl":"10.5114/ada.2024.142576","url":null,"abstract":"<p><strong>Introduction: </strong>The role of calprotectin in psoriasis still remains unclear.</p><p><strong>Aim: </strong>To elucidate the associations between the concentrations of serum and faecal calprotectin (CP) and the severity of psoriasis in 20 patients with moderate-to-severe plaque psoriasis and 20 healthy individuals.</p><p><strong>Material and methods: </strong>The CP levels as well as the disease severity including Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA) score and Dermatology Life Quality Index (DLQI) were assessed.</p><p><strong>Results: </strong>The median serum CP level in the psoriasis group was notably higher at 112.24 μg/l (interquartile range, IQR: 81.39-206.82 μg/l) compared to 60.31 μg/l (IQR: 37.41-81.54 μg/l) in the control group (<i>p</i> = 0.001), while the median faecal CP levels were similar between the two groups: 15.00 μg/g (IQR: 6.20-36.13 μg/g) in psoriasis patients and 13.00 μg/g (IQR: 10.26-30.15 μg/g) in controls (<i>p</i> = 0.766). No significant correlations between serum and faecal CP level and the PASI, BSA and DLQI were found.</p><p><strong>Conclusions: </strong>Despite the fact that patients with moderate-to-severe plaque psoriasis seem to present general higher blood calprotectin levels than healthy individuals, they are still within the population cut-off value. The elevated blood calprotectin levels are not conclusively linked to increased severity of psoriasis or to the deterioration in quality of life. Also, in individuals with psoriasis, gastrointestinal inflammation does not differ markedly from healthy controls.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"487-494"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitization to α-gal and omega-5-gliadin in patients with chronic urticaria: clinical implications and need for targeted testing.","authors":"Vesna Vukičević Lazarević, Marina Božan, Ivica Lokner, Alda Ranogajec","doi":"10.5114/ada.2024.144401","DOIUrl":"10.5114/ada.2024.144401","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic urticaria (CU) is defined as the presence of recurring hives and/or angioedema lasting more than 6 weeks. The precise impact of food allergies, particularly to galactose-α-1,3-galactose (α-gal) and omega-5-gliadin (O5G), on the development of CU is not well established.</p><p><strong>Aim: </strong>The study examines the frequency of sensitisation to these allergens and their clinical significance in individuals with CU.</p><p><strong>Material and methods: </strong>We recruited 100 adults newly diagnosed with CU to evaluate the presence of specific immunoglobulin E antibodies and allergies to α-gal and O5G. The patients were categorised into three groups based on their specific IgE levels: those sensitised to α-gal, those sensitised to O5G, and those not sensitised to either. Demographic, clinical, and laboratory variables were compared across the groups.</p><p><strong>Results: </strong>The findings indicated that 5% of the cohort was sensitised to α-gal, and 4% showed sensitivity to O5G, while only 4% of patients had a convincing history of food allergy (two to red meat and two to wheat). The sensitised groups exhibited the greatest levels of total IgE, and had a higher proportion of males. The α-gal group showed higher levels of specific IgE to Ascaris lumbricoides than the group without sensitisation. The groups had similar features in all other assessed aspects.</p><p><strong>Conclusions: </strong>Our CU cohort's sensitivity and convincing food allergy to α-gal and O5G were comparatively modest. While routine screening may not be essential, focused testing of individuals with severe or uncommon symptoms might enhance the accuracy of diagnosis and treatment.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"500-504"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric-onset hidradenitis suppurativa: a case series of 42 patients.","authors":"Aleksandra Górecka, Wioletta Barańska-Rybak, Miłosz Lewandowski, Elżbieta Szymańska, Zuzanna Świerczewska, Irena Walecka","doi":"10.5114/ada.2024.144517","DOIUrl":"10.5114/ada.2024.144517","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa is a chronic, recurring skin condition characterized by inflammation of the terminal hair follicle. It presents as painful, deep-seated, inflamed lesions such as nodules, fistulas, and abscesses. While the mean onset age for hidradenitis suppurativa is typically between 21 and 29 years, the condition can also manifest in childhood.</p><p><strong>Aim: </strong>To review the clinical and demographic characteristics of pediatric-onset hidradenitis suppurativa patients.</p><p><strong>Material and methods: </strong>We present a case series of 42 patients with pediatric-onset hidradenitis suppurativa (onset age 0-18 years) and their management from two tertiary referral centres. Demographic, clinical, and laboratory data were assessed at the Department of Dermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland, and the Department of Dermatology, Venereology, and Allergology, Medical University of Gdansk, Poland, from January 2000 to May 2023. This report details the epidemiology, clinical course, and management of the reported pediatric-onset hidradenitis suppurativa cases.</p><p><strong>Results: </strong>The median age of onset in our patients was 14 years (range: 5-17). The cohort comprised 20 (48%) males and 22 (52%) females. The most frequent lesion locations were in the inguinal folds and armpits, with additional occurrences in the buttocks and lower abdomen. Common comorbidities included obesity, hypothyroidism, and affective disorders. The treatment regimen for most patients involved topical clindamycin, systemic antibiotics, oral retinoids, and surgical excisions. Additionally, biologic treatments such as adalimumab, infliximab, and secukinumab were administered.</p><p><strong>Conclusions: </strong>This study affirms that the clinical course and treatment methods in patients with pediatric-onset hidradenitis suppurativa are similar to the adult-onset form. Improved disease awareness enables earlier diagnosis, preventing the deterioration of skin lesions, a decrease in quality of life, and the onset of comorbidities, especially affective disorders, which are prevalent among patients with hidradenitis suppurativa.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"525-529"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection.","authors":"Daniel Nolberczak, Aleksandra Lesiak, Rafał Czajkowski, Igor Aleksander Bednarski, Joanna Narbutt","doi":"10.5114/ada.2024.144522","DOIUrl":"10.5114/ada.2024.144522","url":null,"abstract":"<p><strong>Introduction: </strong>Despite multiple clinical presentations of long COVID, the most common symptom encountered by the patients is fatigue which significantly impacts daily functioning and quality of life. There are, however, multiple unanswered questions regarding the treatment of fatigue among long COVID patients. Several studies highlighted that repetitive exposure to blue light may alleviate the fatigue in different groups of patients but the studies on the efficacy of blue light therapy in treatment of fatigue in long COVID patients are lacking.</p><p><strong>Aim: </strong>To evaluate the effects of blue light therapy in treatment of fatigue among COVID-19 survivors.</p><p><strong>Material and methods: </strong>The study comprised of 43 adults who underwent COVID-19 infection with a subjective feeling of fatigue 4 weeks after the infection. All participants underwent 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week. All participants were assessed using the Fatigue Severity Scale (FSS), Short Form 36 Vitality Subscale (SF-36) and Dermatology Life Quality Index (DLQI). Serum samples were taken to measure the levels of tryptophan, kynurenine, kynurenic acid, quinolinic acid and serotonin before and after irradiation.</p><p><strong>Results: </strong>Irradiation with blue light resulted in a significant decrease in FSS and DLQI as well as in an increase in SF-36 and serum levels of tryptophan, kynurenine and serotonin.</p><p><strong>Conclusions: </strong>Our study shows that blue light therapy could be used as adjunctive treatment of fatigue and provide an opportunity for further scientific inquiries.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"515-520"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pruritus prevalence and characteristics in Care and Treatment Facility and Geriatric Outpatient Clinic patients: a cross-sectional study using a standardized pruritus questionnaires.","authors":"Paula Mazan, Aleksandra Lesiak, Małgorzata Skibińska, Monika Rynkowska-Kidawa, Igor Bednarski, Dorota Sobolewska-Sztychny, Marcin Noweta, Joanna Narbutt","doi":"10.5114/ada.2024.144478","DOIUrl":"10.5114/ada.2024.144478","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic pruritus is one of the most common symptoms in geriatric patients. Pathogenesis of pruritus is multifactorial.</p><p><strong>Aim: </strong>To evaluate the prevalence and characteristics of pruritus in geriatric patients and to characterise pruritus and explore its possible underlying causes.</p><p><strong>Material and methods: </strong>The study included 132 patients of 65 years of age or older. The intensity of itch was assessed by Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS), xerosis was assessed by overall skin dryness scale (ODS). Patients were asked to complete the 10-Item Pruritus Severity Scale (10-PSS).</p><p><strong>Results: </strong>Patients with pruritus had significantly higher glucose levels and incidence of xerosis compared to those without pruritus. Patients with anaemia had significantly higher 10-PSS scores than those without. A high correlation was found between 10-PSS, NRS and VAS scales. The incidence of pruritus was significantly higher in patients using antihypertensives, antidiabetics and/or statins compared to those who did not use these medications.</p><p><strong>Conclusions: </strong>One of the most common causes of pruritus is xerosis. It is essential to provide appropriate education to patients and caregivers on the use of emollients. Therefore, the development of recommendations would be desirable. Many drugs commonly used in elderly patients may be responsible for pruritus. An in-depth investigation is necessary as pruritus may be the only symptom or it may precede the appearance of typical skin lesions in the course of certain dermatoses for many months.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"463-472"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative study between fractional microneedling radiofrequency with systemic isotretinoin and fractional microneedling alone in the treatment of rosacea.","authors":"Anwar Issa Hasan, Kholod A Ali, Tuqa Mohammed Latif","doi":"10.5114/ada.2024.142597","DOIUrl":"10.5114/ada.2024.142597","url":null,"abstract":"<p><strong>Introduction: </strong>Rosacea is a chronic inflammatory disease presenting with facial flushing, non-transient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. The pathogenesis of rosacea is not fully understood, but immune dysfunction, Demodex infection, neurovascular dysregulation, and exposure to ultraviolet radiation represent contributing factors.</p><p><strong>Aim: </strong>To evaluate and compare effectiveness of fractional micro-needling radiofrequency with systemic isotretinoin and micro-needling alone in the treatment of rosacea.</p><p><strong>Material and methods: </strong>A cross-sectional comparative study between fractional microneedling radiofrequency with systemic isotretinoin and micro-needling alone in the treatment of rosacea was carried out in a private outpatient clinic and Al-Yarmouk teaching hospital from January 2022 to June 2023. Group A comprised 25 patients treated with systemic isotretinoin (10 mg/day) for 6 weeks and fractional microneedling radiofrequency for 16 weeks. Patients received a session every 2 weeks during the first 2 months of treatment then one session per month. Group B comprised 25 patients treated with fractional microneedling radiofrequency for 16 weeks. The patients received a session every 2 weeks during the first 2 months of treatment then one session per month. Measurement of baseline serum lipid profile, complete blood count, and liver enzyme levels was done to all patients receiving isotretinoin. All patients in both groups were instructed to use sunscreen and emollients. Follow-up of all patients was carried out for 3 months after treatment. Patients were assessment according to the Grade system of rosacea, patient satisfaction, and relapse rate. Relapse rate: no relapse (0), relapse (1). Patient satisfaction: poor (0), fair (1), and good (2).</p><p><strong>Results: </strong>There was no significant difference in the mean severity score for rosacea between group A and group B, before, after 8 weeks, and after 16 weeks. Patients in group A showed higher good satisfaction (72%) than group B (32%). During the follow-up period the relapse rate was higher in group B (32%) than in group A (16%), the percentage reduction (response rate) of the mean of severity score was 41.37% after 8 weeks and 91.37% after 16 weeks in group A, and 34.48% after 8 weeks and 82.75% after 16 weeks in group B.</p><p><strong>Conclusions: </strong>Fractional microneedling radiofrequency is a safe and effective method in the treatment of rosacea, and so it can be used when there are contraindications to other lines of therapy, when patients are resistant to long-term oral therapy, and when patients (including pregnant women) choose not to take oral or topical drugs.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 5","pages":"495-499"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}